Osteosarcoma: Clinical Trials

87 trials for Osteosarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

87 completed. 87 Phase 1, 21 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 187Completed 87
Phase 221Completed 21

Follow Osteosarcoma: new trials by email Literature Review of Osteosarcoma trials Research Report on Osteosarcoma

Trials (filtered) newest first · largest first

All 87 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma
intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) - Osteosarcoma, Bone Cancer
Phase 1 / Phase 2CompletedShanghai 6th People's Hospital102024-12-032025-12-29
Regorafenib in Patients With Refractory Primary Bone Tumors
Regorafenib - Osteosarcoma, Ewing Sarcoma of Bone
Phase 1 / Phase 2CompletedInstitute of Mother and Child, Warsaw, Poland302022-04-282026-10-07
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Surufatinib in combination with Gemcitabine - Solid Tumor, Lymphoma
Phase 1 / Phase 2CompletedHutchmed132021-11-302024-06-07
A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
Azenosertib, Gemcitabine - Osteosarcoma
Phase 1CompletedK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc312021-08-012026-04-03
SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients
Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy - Ewing Sarcoma
Phase 1 / Phase 2CompletedSarcoma Alliance for Research through Collaboration372021-01-052025-12-17
Cabozantinib With Topotecan-Cyclophosphamide
Cabozantinib, Topotecan, Cyclophosphamide - Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma
Phase 1CompletedDana-Farber Cancer Institute122020-12-232023-02-15
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Abemaciclib, Irinotecan, Temozolomide - Relapsed Solid Tumor, Refractory Solid Tumor
Phase 1 / Phase 2CompletedEli Lilly and Company472020-11-092026-03-02
Indocyanine Green (ICG) Guided Tumor Resection
Indocyanine Green - Neoplastic Disease, Solid Tumor
Phase 1CompletedSt. Jude Children's Research Hospital2152020-02-072026-09-14
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Gemcitabine, Nab-paclitaxel - Cancer
Phase 1CompletedEmory University242018-08-272024-10-04
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Natural Killer (NK) Cells, ALT803 - Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 1CompletedBrenda Cooper, MD142018-05-222023-02-21
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
Eribulin mesilate, Irinotecan hydrochloride - Refractory or Recurrent Solid Tumors, Rhabdomyosarcoma
Phase 1 / Phase 2CompletedEisai Inc.402018-03-052022-06-28
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors
Laboratory Biomarker Analysis, Pepinemab, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma
Phase 1 / Phase 2CompletedChildren's Oncology Group262018-01-312024-07-15
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Nab-Rapamycin, Nivolumab - Ewing Sarcoma, PEComa
Phase 1 / Phase 2CompletedSarcoma Oncology Research Center, LLC342017-08-242025-02-17
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin - Soft Tissue Sarcoma, Bone Sarcoma
Phase 1 / Phase 2CompletedGrupo Espanol de Investigacion en Sarcomas1972017-05-312024-08-13
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
Enoblituzumab - Neuroblastoma, Rhabdomyosarcoma
Phase 1CompletedMacroGenics252016-12-012022-02-08
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex - Ewing's Sarcoma, Ewing Family of Tumors
Phase 1CompletedGradalis, Inc.72016-10-012023-11-13
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
TB-403 20mg/kg, TB-403 50mg/kg, TB-403 100mg/kg - Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)
Phase 1CompletedOncurious NV182016-05-012021-01-13
NAC to Prevent Cisplatin-induced Hearing Loss
N-Acetylcysteine - Neuroectodermal Tumors, Primitive, Liver Neoplasms
Phase 1CompletedChildren's Hospital Los Angeles522016-03-012023-04-18
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
Abemaciclib - Diffuse Intrinsic Pontine Glioma, Brain Tumor, Recurrent
Phase 1CompletedEmory University532016-02-012023-10-26
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)1402015-03-302023-10-17

Showing 20 of 87. Sign in to see all of them.

Narrower conditions

Sarcoma (41)  ·  Sarcoma, Ewing (41)  ·  Neuroblastoma (40)  ·  Rhabdomyosarcoma (30)  ·  Wilms Tumor (23)  ·  Neuroectodermal Tumors, Primitive, Peripheral (22)  ·  Neoplasms (18)  ·  Medulloblastoma (17)  ·  Melanoma (17)  ·  Astrocytoma (14)  ·  Carcinoma, Non-Small-Cell Lung (12)  ·  Breast Neoplasms (11)  ·  Carcinoma, Renal Cell (11)  ·  Familial ependymoma (11)

Broader conditions

Neoplasms by Histologic Type (87)  ·  Neoplasms, Bone Tissue (87)  ·  Neoplasms, Connective Tissue (87)  ·  Neoplasms, Connective and Soft Tissue (87)  ·  Neoplasms (69)  ·  Neoplasms, Glandular and Epithelial (56)  ·  Neoplasms by Site (55)  ·  Neoplasms, Nerve Tissue (55)  ·  Neoplasms, Neuroepithelial (52)  ·  Neuroectodermal Tumors (51)  ·  Neoplasms, Germ Cell and Embryonal (47)  ·  Sarcoma (46)  ·  Neuroectodermal Tumors, Primitive (44)  ·  Female Urogenital Diseases (35)  ·  Female Urogenital Diseases and Pregnancy Complications (35)

Interventions

Irinotecan (9)  ·  Cyclophosphamide (8)  ·  Filgrastim (7)  ·  Temozolomide (7)  ·  Methotrexate (6)  ·  Gemcitabine (5)  ·  Granulocyte Colony-Stimulating Factor (5)  ·  Ifosfamide (5)  ·  Leucovorin (5)  ·  Etoposide (4)  ·  Busulfan (3)  ·  Carboplatin (3)  ·  Cisplatin (3)  ·  Doxorubicin (3)  ·  Melphalan (3)

Sponsors

National Cancer Institute (NCI) (17)  ·  St. Jude Children's Research Hospital (5)  ·  Children's Oncology Group (4)  ·  Emory University (4)  ·  National Institutes of Health Clinical Center (CC) (4)  ·  Memorial Sloan Kettering Cancer Center (3)  ·  Celgene (2)  ·  City of Hope Medical Center (2)  ·  Gradalis, Inc. (2)  ·  M.D. Anderson Cancer Center (2)  ·  Pfizer (2)  ·  Sarcoma Alliance for Research through Collaboration (2)  ·  University of Louisville (2)  ·  Valerio Therapeutics (2)  ·  AeRang Kim (1)

Countries

United States (77)  ·  United Kingdom (10)  ·  France (7)  ·  Italy (6)  ·  Spain (6)  ·  Australia (4)  ·  Canada (4)  ·  Germany (4)  ·  Poland (3)  ·  Switzerland (2)  ·  Argentina (1)  ·  Belgium (1)  ·  China (1)  ·  Czechia (1)  ·  Denmark (1)

Top investigators

Elizabeth Fox, MD (2)  ·  Holly Meany, MD (2)  ·  AeRang Kim, MD (1)  ·  AeRang Kim, MD, PhD (1)  ·  Alba Rubio (1)  ·  Andrew Cluster, M.D. (1)  ·  Andrew Saunders, MD (1)  ·  Anna Pawlowska, MD (1)  ·  Anna Raciborska, Prof. (1)  ·  Antonio Casado (1)  ·  Arkadiusz Dudek, MD (1)

Results publications

PMID 31401903, PMID 32192573, PMID 15814645, PMID 16234526, PMID 16551859, PMID 16914576, PMID 18048828, PMID 18281544, PMID 18470481, PMID 19075272, PMID 19430790, PMID 20036194, PMID 20044751, PMID 20226028, PMID 20407240, PMID 20460632, PMID 22186789, PMID 22682017, PMID 23255417, PMID 23382028, PMID 23664013, PMID 24089446, PMID 24711551, PMID 25452614, PMID 25917459, PMID 26154941, PMID 26181034, PMID 27109631, PMID 27932229, PMID 28295221, PMID 28494338, PMID 29544202, PMID 29931504, PMID 30410720, PMID 30477937, PMID 31013172, PMID 31553693, PMID 31876107, PMID 32169872, PMID 32554315, PMID 33203665, PMID 33289920, PMID 33364285, PMID 34157616, PMID 34383370, PMID 34416158, PMID 34416160, PMID 34452019, PMID 34562750, PMID 37194488

NIH funding

U01CA097452 (3), P30CA008748 (2), U01CA069856 (2), UM1CA097452 (2), 2016 (1), 2019 (1), 2023 (1), N01CM62206 (1), P30CA023108 (1), P30CA033572 (1), P30CA043703 (1), P30CA072720 (1), U01CA099168 (1), U01CA236220 (1)